The reshoring trend isn't about replicating traditional manufacturing. Instead, the U.S. gains a competitive advantage by leveraging automation and robotics, effectively trading labor costs for electricity costs. This strategy directly challenges global regions that rely on exporting cheap human labor.

The trend of moving manufacturing to countries like Mexico or Vietnam to avoid China tariffs is often driven by Chinese companies themselves. They establish clone factories abroad, sometimes with Chinese labor, meaning the economic benefits largely still flow back to China.

Despite tariffs making imports more expensive, moving furniture production back to the US is seen as unrealistic. The primary obstacle is not financial, but a critical shortage of trained workers who can and want to do the work, a deficit that tariffs cannot fix.

To compete with China in manufacturing, the US can't rely on labor volume but on productivity from AI and robotics. This requires eliminating the friction of distance between R&D talent (in the Bay Area) and factory floors, making talent-proximate manufacturing parks a strategic necessity.

The U.S. industrial strategy isn't pure "reshoring" but "friend-shoring." The goal is to build a global supply chain that excludes China, not to bring all production home. This creates massive investment opportunities in allied countries like Mexico, Vietnam, Korea, and Japan, which are beneficiaries of this geopolitical realignment.

It's naive to expect private companies to reverse the offshoring of chip manufacturing, a trend they initiated to maximize profits. Pat Gelsinger argues that markets don't price in long-term geopolitical risk, making substantial, long-term government industrial policy essential to bring supply chains back.

Companies cannot compete on labor costs in the US. According to the Reshoring Institute, if labor constitutes more than 50% of a product's build cost, it is not a candidate for US reshoring. Success hinges on automating production to extract labor, making high-capital sectors like pharma more suitable.

While tariffs affected sourcing, the COVID-19 pandemic was the main catalyst for pharma reshoring. The crisis exposed critical vulnerabilities in global supply chains for essential precursors and chemicals, creating a stronger impetus for companies to establish local manufacturing than trade policy alone.

While US tariff policies aim to bring pharmaceutical production back onshore, the immediate beneficiaries are likely to be contract manufacturers. Building new proprietary facilities is a slow and expensive process, so companies will lean on agile contract partners to quickly diversify their supply chains in the interim.